舌下舒芬太尼用于创伤早期疼痛管理的随机对照试验
这项前瞻性多中心开放标签随机试验纳入150例中重度疼痛的创伤患者,比较舌下舒芬太尼与标准治疗。
要点
- 舌下舒芬太尼未在30分钟时比标准治疗更有效降低创伤疼痛评分。
- 标准治疗组在医护整体评估中获良好或优秀评分的患者更多。
- 两组不良事件(恶心、呕吐、头痛、头晕、缺氧、低血压、需高级气道)无差异。
核心结论
- 在创伤中重度疼痛患者中,舌下舒芬太尼与标准治疗在30分钟时的VNRS评分无差异。
- 不良事件发生率两组无差异。
研究设计与样本
- 前瞻性多中心、开放标签、随机对照试验,纳入LITES网络内一级创伤中心。
- 150例患者按1:1随机分配至舌下舒芬太尼组或标准治疗组,入组时间2022年7月至2024年1月。
- 纳入标准:创伤评估、18-70岁、VNRS(0-100)≥50、在急诊停留至少30分钟。
- 排除标准:囚犯、孕妇、阿片类过敏、需气道管理、BMI>40、显著呼吸抑制、疑似胃肠道梗阻或其他镇痛禁忌。
主要发现
- 研究人群平均年龄48岁(SD 15),女性占32%,损伤机制主要为钝性伤(96%)。
- 恶心、呕吐、头痛、头晕、缺氧、低血压或需高级气道的发生率无差异。
临床怎么用
- 对于创伤中重度疼痛患者,舌下舒芬太尼可作为标准治疗之外的选项,但未显示30分钟镇痛优势。
- 需结合医护整体评估选择镇痛方案,标准治疗在整体评估中表现更优。
局限性
- 开放标签设计可能引入偏倚。
- 仅评估30分钟时间点,未反映更长期镇痛效果。
- 排除需气道管理、BMI>40等患者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain management is essential in trauma. Sufentanil is a potent sublingual opioid analgesic with no active metabolites and rapid onset relative to oral medications. We hypothesize that compared to standard care, Sufentanil reduces the verbally administered numerical pain scale (VNRS) at 30 minutes. METHODS: We performed a prospective multicenter, open-label, randomized trial utilizing level-1 trauma centers from within the Linking Investigator in Trauma and Emergency Services (LITES) network. Participants were randomly assigned in a 1:1 ratio to either sublingual sufentanil or standard care. We enrolled 150 patients from July 2022 to January 2024. The study was approved by the human subjects research protection offices of the University of Pittsburgh and the Department of Defense. Subjects were eligible if they had a trauma evaluation, were 18 to 70, had a VNRS (0-100) score ≥50, and remained in the ED for at least 30 minutes. We excluded patients who were prisoners, pregnant, allergic to opioids, required airway management, body mass index (BMI) >40, significant respiratory depression, suspected gastrointestinal obstruction, or other contraindication to analgesics. The primary outcome was the VNRS for clinical pain measurement (0-100) at 30 minutes after treatment. Secondary outcomes included adverse events (hypoxia, hypotension, need for airway management) and the incidence of nausea/vomiting/headache/dizziness requiring treatment. We hypothesize that sublingual sufentanil as compared to emergency department standard care, will reduce the VNRS at 30 minutes. RESULTS: The study population had a mean age of 48 years (standard deviation [SD] 15) and was 32% female. The mechanism of injury was mostly blunt (96%). The VNRS at 30 minutes was 67 (SD 25) for the entire cohort, 66 (SD 23) in the sufentanil group, and 68 (SD 27) in the standard care group ( P = .37). The Health care Professional Global Assessment (HPGA) at 30 minutes showed decreased pain scores in the standard care group compared to sufentanil, with standard care having more patients scored as good or excellent ( P = .009). There was no difference in the incidence of nausea, vomiting, headache, dizziness, hypoxia, hypotension, or need for an advanced airway. CONCLUSIONS: In this cohort of trauma patients with moderate to severe pain, the VNRS at 30 minutes after administration of analgesics did not differ between sublingual sufentanil and standard care. Adverse events did not differ between the groups suggesting the sublingual sufentanil in this population.
引用
- Guyette FX, Chaudhary P, Vincent LE, et al. A Randomized Controlled Trial of Sublingual Sufentanil in Early Management of Pain in Trauma. Anesth Analg. 2025. PMID: 39919020. doi:10.1213/ANE.0000000000007384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。